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Abstract
Background: Lysosomal acid lipase (LAL) controls development and homeostasis of myeloid lineage cells. Loss of the
lysosomal acid lipase (LAL) function leads to expansion of myeloid-derived suppressive cells (MDSCs) that cause
myeloproliferative neoplasm.
Methodology/Principal Findings: Affymetrix GeneChip microarray analysis identified detailed intrinsic defects in Ly6G
+
myeloid lineage cells of LAL knock-out (lal2/2) mice. Ingenuity Pathway Analysis revealed activation of the mammalian
target of rapamycin (mTOR) signaling, which functions as a nutrient/energy/redox sensor, and controls cell growth, cell
cycle entry, cell survival, and cell motility. Loss of the LAL function led to major alteration of large GTPase and small GTPase
signal transduction pathways. lal2/2 Ly6G
+ myeloid cells in the bone marrow showed substantial increase of cell
proliferation in association with up-regulation of cyclin and cyclin-dependent kinase (cdk) genes. The epigenetic
microenvironment was significantly changed due to the increased expression of multiple histone cluster genes, centromere
protein genes and chromosome modification genes. Gene expression of bioenergetic pathways, including glycolysis,
aerobic glycolysis, mitochondrial oxidative phosphorylation, and respiratory chain proteins, was also increased, while the
mitochondrial function was impaired in lal2/2 Ly6G
+ myeloid cells. The concentration of reactive oxygen species (ROS) was
significantly increased accompanied by up-regulation of nitric oxide/ROS production genes in these cells.
Conclusions/Significance: This comprehensive gene profile study for the first time identifies and defines important gene
pathways involved in the myeloid lineage cells towards MDSCs using lal2/2 mouse model.
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Introduction
Myeloid-derived suppressive cells (MDSCs) are heterogeneous
populations that express CD11b and Gr-1 antigens. MDSCs
actively participate in inflammation-induced pathogenic processes
in various diseases (i.e. cancer) by suppressing T lymphocytes
[1,2,3]. We previously reported that the neutral lipid metabolic
pathway controlled by lysosomal acid lipase (LAL) plays a critical
role in development and homeostasis of MDSCs [4,5]. LAL
hydrolyzes cholesteryl esters and triglycerides in the lysosome of
cells to generate free cholesterol and free fatty acids. Ablating LAL
(lal2/2) in mice led to aberrant expansion of MDSCs (.40% in
the blood, and .70% in the bone marrow) that arise from
dysregulated production of myeloid progenitor cells in the bone
marrow [4]. Ly6G
+ MDSCs in lal2/2 mice show strong
immunosuppression on T cells, which contributes to impaired T
cell proliferation and function in vivo [4,5]. As a consequence of
myeloproliferative neoplasm, severe pathogenic phenotypes in
multiple organs are observed in lal2/2 mice, including the adult
lung, liver, spleen, thymus, adrenal glands, and small intestine,
which are all associated with MDSCs infiltration [4,6,7,8,9,10].
Over-expression of LAL downstream genes in myeloid lineage
cells driven by the 7.2 kb c-fms promoter/intron 2 induces chronic
inflammation, immunosuppression and tumorigenesis in vivo
[11,12,13].
Given the important role in inflammation and tissue pathogen-
esis, it is essential to elucidate the intrinsic molecular mechanisms
governing MDSCs development and homeostasis in lal2/2 mice.
At the moment, up-regulated genes related to amino acid
metabolism (i.e. L-arginine) and production of reactive oxygen
(ROS)/nitrogen species are well studied and serve as parameters
to define MDSCs [14,15]. In this report, we aim at identifying a
comprehensive gene profile to define pathways that are involved in
MDSCs development in lal2/2 mice by GeneChip microarray
analysis. The results showed that the mammalian target of
rapamycin (mTOR) signaling, which functions as a nutrient/
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30701energy/redox sensor, and controls cell growth, cell cycle entry, cell
survival, and cell motility, is activated in bone marrow MDSCs
during LAL deficiency.
Materials and Methods
Ethics Statement and Animal Care
All scientific protocols involving the use of animals have been
approved by the Institutional Animal Care and Use Committee of
Indiana University School of Medicine and followed guidelines
established by the Panel on Euthanasia of the American
Veterinary Medical Association. Protocols involving the use of
recombinant DNA or biohazardous materials have been reviewed
by the Biosafety Committee of Indiana University School of
Medicine and followed guidelines established by the National
Institutes of Health. Animals were housed under Institutional
Animal Care and Use Committee-approved conditions in a
secured animal facility at Indiana University School of Medicine.
S6 and E4-BP analysis
Fluorescence activated cell sorting (FACS) analysis was
performed on single cells from the bone marrow of 5-month-old
lal+/+ and lal2/2 mice. Bone marrow cells were prepared as
previously described [11]. Approximately 1 to 2610
6 cells from
various organs in FACS buffer were blocked with FcR blocking
antibodies (BD Pharmingen, San Diego, CA) followed by
incubation with APC anti-mouse CD11b and PE rat anti-mouse
Ly6G (1A8, BD Bioscience). Cells were fixed and permeabilized
using BD Cytofix/Cytoperm
TM Fixation/permeabilization Kit
according to the manufacture’s instruction, followed by labeling
with anti-pS6 (ser235/236) and anti-p4E-BP (Thr37/46) antibod-
ies (1:50 dilution, Cell Signaling Technology, Beverly, MA) at 4uC
overnight. Cells were analyzed on a LSRII machine (BD
Biosciences, San Jose, CA). Data were analyzed using the BD
FACStation
TM Software (BD Biosciences). Quadrants were
assigned using isotype control mAb.
MDSCs RNA isolation
Single cells from bone marrow of 5-month-old lal+/+ and
lal2/2 mice (n=5) were stained with anti-Ly6G
+ antibody,
followed by positive magnetic selection using anti-biotin micro-
beads following the manufacture’s instructions (Miltenyi Biotec,
Auburn, CA). The purity of the Ly6G
+ MDSC population was
typically higher than 90%. Total RNAs from isolated Ly6G
+
MDSCs were purified using the Qiagen total RNA purification kit
(Qiagen, Valencia, CA). RNA concentrations were measured with
Spectra Max 190 (Molecular Devices, Sunnyvale, CA).
Affymetrix GeneChip microarray analyses
The quality of the total RNA was checked by the Agilent
Bioanalyzer 2100 (Hewelett Packard) using the RNA 6000 Pico
Assay. To create biotin labeled cDNA products, 20 nanograms of
total RNA was used. Double stranded target cDNA was
synthesized using a random hexamer with a T7 promoter. Target
sense transcript cRNA was generated from the double-stranded
cDNA template using the Whole Transcript cDNA Synthesis and
Amplification Kit. cDNA was regenerated using a reverse
transcription reaction randomly primed with a mix containing
dUTP. After hydrolysis of the cRNA with RNase H, the sense
strand of cDNA was purified using the Affymetrix sample cleanup
module, fragmented by incubation with UDG (uracil DNA
glycosylase) and APE 1 (apurinic/apyrimidicendonuclease 1),
and terminally biotin-labeled with TdT (terminal deoxynucleotidyl
transferase) using the WT Terminal Labeling Kit. Biotinylated
sense strand fragments were hybridized to Affymetrix Mouse Gene
1.0 ST GeneChips using the Hybridization Control and
Hybridization Wash and Stain kits at 45uC for 18 hrs. The
stained array was scanned using an Affymetrix GeneChip Scanner
3000 7G to generate the CEL files. Primary quality control was
performed using the Affymetrix Expression Console. The chip
data were imported with Partek Genomics Suite 6.5 (Partek, Inc.,
St Louis, MO), normalized and summarized using the RMA
(Robust Multiarray Average) algorithm. The relative log expres-
sion was examined to ensure that the data were properly corrected
by normalization and that there were no outliers. Mv A plots were
generated to examine the reproducibility of the replicates. To
identify expression changes between genotypes, a two-way
ANOVA was performed by using the methods of moments [16]
to partition the effect of tissue and genotype. Genes differentially
expressed in lal2/2 mice vs lal+/+ mice were identified at a false
positive rate (FDR) of 0.05 and fold change $2. The unprocessed
microarray data is available at Gene Expression Ominibus
Database (GEO) at NCBI (accession number GSE 29401).
Pathway and functional classification
Significantly affected or differentially expressed genes were
subjected to an intensive search to identify biological functions.
Functional pathway gene ontology and network analysis were
executed using Ingenuity Pathway Analysis (IPA) (Ingenuity
Systems, Mountain View, CA), Partek (Partek Inc., St. Louis,
MO), public information and literature references. The enriched
functional categories were determined by Fisher Exact Test using
the corresponding murine genome as a reference dataset. The
significance was set at p-value,0.05. The differentially expressed
genes were grouped into various categories. To cluster gene
expression profiles, Hierarchical cluster analysis of the significantly
expressed genes was performed using Partek genomic suite 6.6 (St.
Louis, MO) which showed the correlated groups of genes and their
expression patterns across all points.
FACS for JC-1 analysis
Mitochondrial membrane potential was measured according to
MitoProbe JC-1 Assay Kit (Molecular Probe, Eugene, OR). Bone
marrow single cells from lal+/+ and lal2/2 mice were suspended
in pre-warmed PBS. Cells were then stained with anti-CD11b,
anti-Ly6G antibody and 10 ml of 200 mM JC-1 dye. After
incubation at 37uC, 5% CO2 for 30 minutes, cells were suspended
by gently flicking the tubes with the warmed PBS and washed
twice. JC-1 was analyzed by flow cytometry in gated
CD11b
+Ly6G
+ cells.
ROS detection
Ly6G
+ cells were isolated from the bone marrow of lal+/+ and
lal2/2 mice with ly6G
+ antibody-coated magnetic beads and
MACS-LS columns according to the manufacturer’s instructions
(Miltenyi Biotec, Auburn, CA). Purified cells were suspended in
pre-warmed PBS. Oxidation-sensitive dye 29-79-dichlorodihydro-
fluorescein diacetate (DCFDA, C6827, Invitrogen, Eugene, OR),
was used to measure ROS production by MDSC. Cells were
incubated at 37uC in pre-warmed PBS in the presence of 2.5 mM
DCFDA for 20 min. Cells were then labeled with APC-conjugated
anti-Ly6G
+ and PE-conjugated anti-CD11b Abs on ice. Analysis
was then conducted by flow cytometry.
Cell Cycle
Bone marrow cells from lal+/+ and lal2/2 mice were stained
with surface markers anti-CD11b and ly6G antibodies (1:200
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PBS, cells were fixed in 1 ml 70% methanol for 1 hour at room
temperature. After cells were washed with PBS, 100 ml of 10 mg/
ml RNAase (Rase LS005649, Worthington Biochemicals, Lake-
wood, NJ) and 1 ml of 50 mg/ml propidium iodide (PI, P4170,
Sigma, Saint Louis, MI) were added and incubated for 30 min at
Figure 1. Affymetrix GeneChip microarray and Ingenuity Pathway analyses of lal2/2 MDSCs. A). Affymetrix GeneChip microarray
analysis of Ly6G
+ MDSCs from the bone marrow of lal+/+ mice and lal2/2 mice. Numbers represent percentages of changed genes in each category
vs total changed genes between lal2/2 mice and lal+/+ mice; B). Differential gene expression of Ly6G
+ MDSCs from the bone marrow of lal+/+ mice
and lal2/2 mice was analyzed by Ingenuity Pathway Analysis. Changed genes in the PPARc pathway, cholesterol biosynthesis and mTOR signaling
pathway are presented; C) Flow cytometry of mTOR downstream effectors S6 and 4E-BP1 in Ly6G
+ MDSCs from the bone marrow of lal+/+ mice and
lal2/2 mice. n=4.
doi:10.1371/journal.pone.0030701.g001
Gene Profile of lal2/2 Bone Marrow MDSCs
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e3070137uC. Cells were washed with PBS. PI-labeled DNA concentra-
tions were analyzed in gated CD11b
+Ly6G
+ cells by FACS
Calibur APC machine. The data were analyzed with ModFit
LT
Tm DNA analysis software (VMFLTMAC3, Verity Software
House, Topsham, ME).
ATP assay
Bone marrow cells (1610
6) were rinsed with PBS and lysed with
ATP-releasing buffer containing 100 mM potassium phosphate
buffer (pH 7.8), 2 mM EDTA, 1 mM dithiothreitol, and 1%
Triton X-100. The ATP concentration of cell lysate was measured
using ATP kit (Invitrogen, Carlsbad, CA) according to the
manufacture’s instruction.
Results
Affymetrix GeneChip microarray and Ingenuity pathway
analyses of Ly6G
+ cells from the lal2/2 bone marrow
In order to identify intrinsic defects of MDSCs in lal2/2 mice,
total RNAs were isolated from Ly6G
+ myeloid cells of the age-
matched wild type and lal2/2 bone marrow. Purified total RNAs
were subjective to the Affymetrix GeneChip microarray study. At
a false positive rate (FDR) of 0.05 and fold change $2, there were
3086 changed genes in lal2/2 bone marrow MDSCs. Major
changes of lal2/2bone marrow MDSCs were observed in G-
protein signaling, cell cycle, chromatin modification and bioener-
getics (Figure 1A). Gene expression of both Ly6G (9.1 fold) and
Ly6C (7.1 fold) was increased in lal2/2 bone marrow MDSCs.
Ingenuity Pathway Analysis revealed alteration of several impor-
tant pathways in lal2/2 bone marrow MDSCs (Figure 1B).
Compared with normal wild-type cells, expression of genes that
are positively or negatively regulated by LAL downstream effector
PPARc was altered. Due to lack of cholesterol generation through
the LAL pathway, genes involved in cholesterol biosynthesis were
increased in lal2/2 bone marrow MDSCs to compensate the loss.
Importantly, genes involved in the mammalian target of
rapamycin (mTOR) singaling pathway were altered in lal2/2
bone marrow MDSCs. The mTOR is a serine/threonine protein
kinase that regulates cell growth, cell proliferation, cell motility,
cell survival, protein synthesis, and transcription in response to
growth factors, and mitogens. mTOR also senses cellular nutrient
and energy levels and redox status [17]. Compared with wild type
mice, mTOR downstream effectors S6 (S6) and 4E-BP1 were
highly phosphorylated in lal2/2 bone marrow MDSCs
(Figure 1C), a strong indication of mTOR activation.
ROS production in lal2/2 bone marrow MDSCs
Since mTOR controls the redox status, and nitric oxide and
reactive oxygen species production are known to play important
roles in MDSCs, genes involved in nitric oxide and ROS
production were investigated in lal2/2 bone marrow MDSCs.
As demonstrated in Figure 2A, expression of these genes was
significantly altered. As a result, the concentration of ROS was
increased 3 times in the Ly6G population of lal2/2 bone marrow
Figure 2. ROS Pathway Analysis of lal2/2 bone marrow MDSCs. A). Differential gene expression of CD11b
+Ly6G
+ MDSCs from the bone
marrow of lal+/+ mice and lal2/2 mice was analyzed by Ingenuity Pathway Analysis. Changed genes in the nitric oxide and reactive oxygen species
production genes are presented; B). ROS production in CD11b
+Ly6G
+ MDSCs from the bone marrow of lal+/+ mice and lal2/2 mice. The ROS signal
was statistically analyzed by mean fluorescent intensity (MFI). Results are means of 4 independent FACS experiments. n=4, **, p,0.01.
doi:10.1371/journal.pone.0030701.g002
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Reduced glutathione (GSH) protects the cell by destroying
hydrogen peroxide and hydroxyl free radicals. Both glutathione
peroxidase (3.0 fold) and glutathione reductase genes (20.1 fold)
showed increased expression in lal2/2 bone marrow MDSCs as
well (Table S2). The gene expression level of glucose 6-phosphate
dehydrogenase that is required for regeneration of GSH from its
oxidized form (GSSG) was increased in lal2/2 bone marrow
MDSCs as well (Table S2).
Gene expression levels of G-protein family in lal2/2
MDSCs
Guanosine nucleotide-binding proteins (G proteins) are involved
in many aspects of cellular functions. They play key roles in signal
transduction and regulation of gene expression in almost all cell
types including immune cells [18]. This group of proteins can be
separated into two classes. The first class is the heterotrimeric G
protein superfamily, consisting of a-, b-, and c-subunit, with the a-
subunit binding the guanosine nucleotides. Many members in this
large G-protein superfamily, including receptors, effectors, het-
erotrimeric Gabc subunits, and the regulators of G-protein
signaling proteins were altered in gene expression in lal2/2
bone marrow MDSCs (Table 1, 2). The second class is the
monomeric low-molecular-weight Ras GTPase superfamily, which
contains more than 100 proteins, and cycles between an inactive
guanosine diphosphate (GDP) and an active GTP-bound form
[19]. As demonstrated in Table 3, 4, 5, gene expression of many
members of the small GTPase superfamily and downstream
effectors were altered in lal2/2 bone marrow MDSCs. It is
known that G-protein family has a tight relationship with the
mTOR activity [20].
Gene expression levels of cell cycle protein family in
lal2/2 MDSCs
The cell cycle consists of four distinct phases: G1 phase, S
phase (synthesis), G2 phase and M phase (mitosis). The G1
checkpoint control mechanism ensures that everything is ready
for DNA synthesis. DNA replication occurs during the S phase.
During the interphase (cell grows), nutrients are accumulated and
DNA is duplicated in cells. The G2 checkpoint control
mechanism ensures that everything is ready to enter the M
phase and divide. During the mitosis (M) phase, the cell splits
itself into two distinct daughter cells. The cell cycle is precisely
controlled by cyclin-dependent kinases (CDKs). CDK activity
requires binding of regulatory subunit cyclins [21]. When
activated by a bound cyclin, CDKs perform phosphorylation
that activates or inactivates target proteins to orchestrate
coordinated entry into the next phase of the cell cycle. Gene
Table 1. Increases of large G-protein superfamily in lal2/2
bone marrow MDSCs.
Genes Symbol Fold
G protein-coupled receptor 137B, pseudogene Gpr137b-ps 11.6
regulator of G-protein signaling 18 Rgs18 9.5
G protein-coupled receptor 84 Gpr84 9.1
G protein-coupled receptor 141 Gpr141 6.3
G protein-coupled receptor 97 Gpr97 5.9
guanylate cyclase activator 1a (retina) Guca1a 3.6
regulator of G-protein signaling 19 Rgs19 3.4
G protein-coupled receptor 108 Gpr108 3.4
GTP-binding protein 8 (putative) Gtpbp8 3.4
IQ motif containing GTPase activating protein 2 Iqgap2 3.3
CAP, adenylate cyclase-associated protein 1 (yeast) Cap1 3.0
G protein-coupled receptor 107 Gpr107 2.7
guanine nucleotide binding protein (G protein),
gamma 12
Gng12 2.7
G protein-coupled receptor kinase 6 Grk6 2.7
Guanosine diphosphate (GDP) dissociation inhibitor 1 Gdi1 2.7
guanine nucleotide binding protein (G protein), beta 1 Gnb12 . 6
GTP binding protein 1 Gtpbp1 2.6
guanine nucleotide binding protein (G protein), alpha
inhibitor 2
Gnai2 2.5
guanine nucleotide binding protein (G protein), beta 5 Gnb52 . 4
ArfGAP with GTPase domain, ankyrin repeat and PH
domain 1
Agap1 2.3
G-protein signalling modulator 2 (AGS3-like, C. elegans) Gpsm2 2.2
developmentally regulated GTP binding protein 1 Drg1 2.2
SLIT-ROBO Rho GTPase activating protein 2 Srgap2 2.2
RAP1, GTP-GDP dissociation stimulator 1 Rap1gds1 2.2
G-protein signalling modulator 3 (AGS3-like, C. elegans) Gpsm3 2.1
guanine nucleotide binding protein, alpha
q polypeptide
Gnaq2 . 1
guanine nucleotide binding protein (G protein),
beta 2
Gnb22 . 0
guanine nucleotide binding protein (G protein),
gamma 5
Gnc52 . 0
doi:10.1371/journal.pone.0030701.t001
Table 2. Decreases of large G-protein superfamily in lal2/2
bone marrow MDSCs.
Genes Symbol Fold
guanine nucleotide binding protein (G protein),
gamma tran
Gnct2 22.0
guanylate binding protein 4 Gbp4 22.2
regulator of G-protein signalling 10 Rgs10 22.2
GTP binding protein (gene overexpressed in
skeletal muscle)
Gem 22.4
SLIT-ROBO Rho GTPase activating protein 3 Srgap3 22.5
guanylate binding protein 3 Gbp3 22.5
GTPase, IMAP family member 8 Gimap8 22.8
purinergic receptor P2Y, G-protein coupled, 14 P2ry14 23.0
GTPase, IMAP family member 1 Gimap1 24.0
guanine nucleotide binding protein-like 3 (nucleolar) Gnl3 24.1
Rap guanine nucleotide exchange factor (GEF) 4 Rapgef4 24.6
G protein-coupled receptor 18 Gpr18 25.5
GTPase, very large interferon inducible 1 pseudogene Gm4759 25.8
guanylate binding protein 1 Gbp1 25.9
G protein-coupled receptor 183 Gpr183 27.5
G protein-coupled receptor 174 Gpr174 27.6
GTPase, IMAP family member 4 Gimap4 29.0
G protein-coupled receptor 171 Gpr171 29.2
GTPase, IMAP family member 6 Gimap6 214.0
doi:10.1371/journal.pone.0030701.t002
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cycle were altered in lal2/2 bone marrow MDSCs (Table 6). In
lal2/2 bone marrow MDSCs, gene expression of all four critical
cyclins (A, B, D, E-type) as well as Cdk1, Cdk2, Cdk5, Cdk9 were
up-regulated compared with wild type MDSCs (Table 6). When
the cell cycle was studied, 4 times more lal2/2 MDSCs (20.96%)
were accumulated in the G2/M phases than wild type MDSCs
(5.35%) (Figure 3A, B), suggesting that lal2/2 bone marrow
Table 3. Increases of monomeric low-molecular-weight Ras
GTPase superfamily in lal2/2 bone marrow MDSCs.
Genes Symbol Fold
RAB3D, member RAS oncogene family Rab3d 7.5
mitogen-activated protein kinase 3 Mapk3 7.3
Shc SH2-domain binding protein 1 Shcbp1 6.8
Rho GTPase activating protein 19 Arhgap19 6.4
mitogen-activated protein kinase-activated protein
kinase 3
Mapkapk3 6.0
multiple EGF-like-domains 9 Megf9 5.9
RAB1B, member RAS oncogene family Rab1b 5.4
mitogen-activated protein kinase 13 Mapk13 5.1
RAB37, member of RAS oncogene family Rab37 5.0
p21 protein (Cdc42/Rac)-activated kinase 1 Pak1 4.9
Ras and Rab interactor 2 Rin2 4.9
RAB11B, member RAS oncogene family Rab11b 4.7
RAB5B, member RAS oncogene family Rab5b 4.4
MAP kinase-activated protein kinase 2 Mapkapk2 4.3
RAB18, member RAS oncogene family Rab18 4.2
RAS related protein 2a Rap2a 4.1
RAB28, member RAS oncogene family Rab28 4.0
Rho guanine nucleotide exchange factor (GEF) 12 Arhgef12 4.0
RAB interacting factor Rabif 3.8
mitogen-activated protein kinase kinase 4 Map2k4 3.8
thymoma viral proto-oncogene 1 interacting protein Aktip 3.8
neuroblastoma ras oncogene Nras 2.8
RAB31, member RAS oncogene family Rab31 3.6
ras homolog gene family, member G Rhog 3.5
CDC42 effector protein (Rho GTPase binding) 3 Cdc42ep3 3.5
Rab interacting lysosomal protein-like 2 Rilpl2 3.4
RAB27A, member RAS oncogene family Rab27a 3.4
RAB24, member RAS oncogene family Rab24 3.3
thymoma viral proto-oncogene 2 Akt2 3.3
mitogen-activated protein kinase kinase 1 Map2k1 3.2
JNK1/MAPK8-associated membrane protein Jkamp 3.2
RAB18, member RAS oncogene family Rab18 3.1
RAS-related C3 botulinum substrate 2 Rac2 3.1
mitogen-activated protein kinase kinase kinase
kinase 4
Map4k4 3.0
mitogen-activated protein kinase kinase kinase 9 Map3k9 3.0
Rho GTPase activating protein 1 Arhgap1 3.0
RAB5C, member RAS oncogene family Rab5c 2.9
RAB23, member RAS oncogene family Rab23 2.8
Ras suppressor protein 1 Rsu1 2.8
Ras-like without CAAX 1 Rit1 2.8
Rac GTPase-activating protein 1 Racgap1 2.8
doi:10.1371/journal.pone.0030701.t003
Table 4. Increases of additional monomeric low-molecular-
weight Ras GTPase superfamily in lal2/2 bone marrow
MDSCs.
Genes Symbol Fold
mitogen-activated protein kinase 7 Mapk7 2.7
RAB22A, member RAS oncogene family Rab22a 2.6
thymoma viral proto-oncogene 1 Akt1 2.6
MAPK scaffold protein 1 Mapksp1 2.5
Rho GTPase activating protein 30 Arhgap30 2.5
RAB11a, member RAS oncogene family Rab11a 2.4
MAPK scaffold protein 1 Mapksp1 2.4
mitogen-activated protein kinase 6 Mapk6 2.4
Rac/Cdc42 guanine nucleotide exchange
factor (GEF) 6
Arhgef6 2.4
RAB7, member RAS oncogene family Rab7 2.3
RAB4B, member RAS oncogene family Rab4b 2.3
ras homolog gene family, member U Rhou 2.3
RAB6, member RAS oncogene family Rab6 2.3
RAB32, member RAS oncogene family Rab32 2.3
mitogen-activated protein kinase associated protein 1 Mapkap1 2.3
MAF1 homolog (S. cerevisiae) Maf1 2.3
Ras homolog enriched in brain Rheb 2.3
Ras association (RalGDS/AF-6) domain family
member 5
Rassf5 2.3
ArfGAP with GTPase domain, ankyrin repeat and PH
domain 1
Agap1 2.3
RAS guanyl releasing protein 4 Rasgrp4 2.3
RAB guanine nucleotide exchange factor (GEF) 1 Rabgef1 2.3
Rho family GTPase 1 Rnd1 2.2
Ras association (RalGDS/AF-6) domain family
member 3
Rassf3 2.2
MAP kinase-activated protein kinase 5 Mapkapk5 2.2
mitogen-activated protein kinase kinase kinase
kinase 2
Map4k2 2.2
Ras and Rab interactor-like Rinl 2.2
RAB35, member RAS oncogene family Rab35 2.2
Srgap2//SLIT-ROBO Rho GTPase activating protein 2 Srgap2 2.2
Rho GTPase activating protein 4 Arhgap4 2.2
Rho GTPase activating protein 11A Arhgap11a 2.2
RAP1, GTP-GDP dissociation stimulator 1 Rap1gds1 2.2
mitogen-activated protein kinase kinase kinase 3 Map3k3 2.1
mitogen-activated protein kinase kinase 3 Map2k3 2.1
mitogen-activated protein kinase kinase 2 Map2k2 2.1
Rab acceptor 1 (prenylated) Rabac1 2.1
Rho GTPase activating protein 15 Arhgap15 2.1
farnesyltransferase, CAAX box, alpha Fnta 2.0
RAP2C, member of RAS oncogene family Rap2c 2.0
RAB43, member RAS oncogene family Rab43 2.0
RAB3 GTPase activating protein subunit 2 Rab3gap2 2.0
doi:10.1371/journal.pone.0030701.t004
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previous BrdU proliferation study [4].
The G1 cyclin-CDK complexes also promote the degradation
of molecules (i.e. cyclins after using) that function as S phase
inhibitors by targeting them for ubiquitination [21]. Once a
protein has been ubiquitinated, it is targeted for proteolytic
degradation by the proteasome. In lal2/2 bone marrow
MDSCs, gene expression of enzymes/protein factors involved
in ubiquitination (Table 7) and proteasome subunits (Table 8)
showed up-regulation, indicating an enhanced protein recycling
activity.
Gene expression levels of histone cluster protein family
and centromere protein family in lal2/2 MDSCs
Cell proliferation and cell cycle are also controlled by the
chromatin activity. The nucleosomes form the basic repeating
units of chromatin in eukaryotes. The composition of the
individual nucleosomes is fundamentally similar and consists of
an octameric core of four types of histones (H2A, H2B, H3 and
H4). The expression of the major histones is tightly regulated
during the cell cycle, and the histones are deposited onto DNA in
a process that is strictly coupled to DNA replication. However,
histone variants are not subject to this stringent regulation, and
are expressed throughout the cell cycle. Histone-variant
exchange activities contribute to gene expression and other
cellular events (i.e. formation of centromeric and telomeric
chromatin during cell cycles) [22]. In lal2/2 bone marrow
MDSCs, gene expression of multiple histone variants were
increased (Table 9). The function of histone deposition onto
DNA is also influenced by interacting with other associated
proteins and by posttranslational modification (such as phos-
phorylation, methylation, and acetylation, polyADP ribosylation
and monoubiquitylation) [22]. Alteration of gene expression of
these factors was observed in lal2/2 bone marrow MDSCs
(Table 7 and Table S1).
During the M phase of cell cycle, the centromeric histones
(i.e. CENPA) are required for chromosome segregation. They
form centromere that is the site of spindle attachment to the
chromosomes during mitosis. Gene expression of multiple
centromeric and telomeric histones along with other M phase
chromosome structural proteins (i.e. kinetochore protein
subunits) was increased in lal2/2 bone marrow MDSCs
(Table 10).
Gene expression levels of metabolic proteins involved in
glycolysis and citric acid cycles in lal2/2 MDSCs
Metabolism provides the cell with the energy and resources to
support cell growth. Glucose serves as a fuel for ATP generation.
Glycolysis occurs in the cytosol. The link between glycolysis and
citric acid cycle is the oxidative decarboxylation of pyruvate to
form acetyl CoA. In the matrix of mitochondrial, the citric acid
cycle is the final common pathway for the oxidation of fuel
Table 5. Decreases of monomeric low-molecular-weight Ras
GTPase superfamily in lal2/2 bone marrow MDSCs.
Genes Symbol Fold
ras homolog gene family, member H Rhoh 22.4
SLIT-ROBO Rho GTPase activating protein 3 Srgap3 22.5
ras homolog gene family, member Q Rhoq 22.7
Rho GTPase activating protein 12 Arhgap12 23.4
thymoma viral proto-oncogene 3 Akt3 23.4
RasGEF domain family, member 1B Rasgef1b 23.5
Rap guanine nucleotide exchange factor (GEF) 4 Rapgef4 24.6
RAS guanyl releasing protein 1 Rasgrp1 24.7
RAB30, member RAS oncogene family Rab30 25.2
RAS, guanyl releasing protein 3 Rasgrp3 210.2
doi:10.1371/journal.pone.0030701.t005
Table 6. Up-regulation of cyclin proteins in lal2/2 bone
marrow MDSCs.
Genes Symbol Fold
cyclin-dependent kinase inhibitor 3 Cdkn3 8.4
cyclin B1 Ccnb1 7.2
cell division cycle 2 homolog A (S. pombe) Cdc2a 6.6
cyclin B2 Ccnb2 5.6
cell division cycle associated 8 Cdca8 5.4
cyclin A2 (S to G2 transition, KO embryonic lethality) Ccna2 5.1
meiotic nuclear divisions 1 homolog (S. cerevisiae) Mnd1 4.5
cell growth regulator with ring finger domain 1 Cgrrf1 4.4
cyclin-dependent kinase inhibitor 2D Cdkn2d 4.2
cyclin-dependent kinase 2 (G1 to S transition) Cdk2 4.0
cyclin-dependent kinase 5 Cdk5 4.0
CDC14 cell division cycle 14 homolog A (S. cerevisiae) Cdc14a 3.8
cell division cycle associated 3 Cdca3 3.5
cell division cycle 45 homolog (S. cerevisiae)-like Cdc45l 3.4
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) Cdkn2c 3.4
cyclin C Ccnc 3.3
cell division cycle 25 homolog C (S. pombe) Cdc25c 3.3
cell division cycle associated 7 Cdca7 3.2
cell division cycle 25 homolog A (S. pombe). Cdc25a 2.9
cell division cycle 20 homolog (S. cerevisiae) Cdc20 2.9
cell division cycle 26 Cdc26 2.7
cyclin D3 Ccnd3 2.6
cell division cycle associated 2 Cdca2 2.6
CDC42 small effector 1 Cdc42se1 2.5
cyclin-dependent kinase 9 (CDC2-related kinase) Cdk9 2.5
cell division cycle 34 homolog (S. cerevisiae) Cdc34 2.4
cell division cycle 2-like 1 Cdc2l1 2.4
cell division cycle 123 homolog (S. cerevisiae) Cdc123 2.3
cyclin-dependent kinase-like 2 (CDC2-related kinase) Cdkl2 2.3
cyclin E2 (G1 to S transition) Ccne2 2.3
cyclin-dependent kinase-like 2 (CDC2-related kinase) Cdkl2 2.3
cell division cycle 2-like 6 (CDK8-like) Cdc2l6 2.3
CDC42 small effector 2 Cdc42se2 2.2
protein interacting with cyclin A1 Proca1 2.3
cyclin G2 Ccng2 2.2
cell division cycle 37 homolog (S. cerevisiae) Cdc37 2.1
cyclin I Ccni 2.1
cyclin B1 interacting protein 1 Ccnb1ip1 22.2
cyclin D2 Ccnd2 22.4
growth arrest specific 5 Gas5 23.3
doi:10.1371/journal.pone.0030701.t006
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biosyntheses. Many enzymes that are involved in the glycolytic
pathway (hexokinase, glucose phosphate isomerase, aldolase,
triosephosphate isomerase, glyceraldehyde-3-phosphate dehydro-
genase, phosphoglycerate kinase, enolase, pyruvate kinase) and the
citric acid cycle (isocitrate dehydrogenase 1, succinate dehydroge-
nase complex, subunit B, malate dehydrogenase 2) were up-
regulated in lal2/2 bone marrow MDSCs (Table 11). In
addition, gene expression of both lactate dehydrogenase A and
B was up-regulated in lal2/2 bone marrow MDSCs (Table 11), a
pathway generally used by cancer cells (Warburg effect). Some
enzymes in the pentose phosphate pathway (energy conservation
for biosynthetic purposes) and glycogen synthesis (storage form of
glucose and metabolic energy) were also up-regulated in lal2/2
bone marrow MDSCs (Table S2).
Gene expression levels of mitochondrial respiratory
assembly and energy generating proteins in lal2/2
MDSCs
Mitochondria are the powerhouse for cells. In order to support
robust cell proliferation, ATP synthesis is required. In mitochon-
drial oxidative phosphorylation, the synthesis of ATP is coupled to
the flow of electrons from NADH or FADH2 to O2 by a proton
gradient across the inner mitochondrial membrane and a series of
electron carriers, such as NADH dehydrogenases and the
cytochromes [23]. The synthesis of ATP is carried out by
mitochondrial ATPase in the inner mitochondrial membrane. In
lal2/2 bone marrow MDSCs, the ATP concentration was
significantly increased compared with wild type mice (Figure 4A).
As demonstrated in Table 12, 13, expression of multiple NADH
dehydrogenase subunits, cytochrome subunits, and mitochondrial
ATPase were all up-regulated in lal2/2 bone marrow MDSCs.
Of the 85 mitochondrial respiratory chain subunits, 13 are
synthesized within the organelle by the mitochondrial ribosome
[24]. Gene expression of multiple mitochondrial ribosomal protein
subunits were also up-regulated in lal2/2 bone marrow MDSCs
(Table S3), indicating the increased activity of protein synthesis
within the mitochondria to meet the demand of ATP production.
Despite increased mitochondrial activities and ATP synthesis, the
membrane potential was reduced (Figure 4B), an indication of the
functional impairment of mitochondria in lal2/2 bone marrow
MDSCs.
Discussion
LAL plays an important role in controlling inflammation.
Genetic ablation of LAL function leads to systemic expansion of
MDSCs. The aggressive behavior of MDSCs in lal2/2 mice
relies on their intrinsic malfunction. The gene profile analysis
reveals the underneath mechanisms by which LAL regulates
MDSCs development and homeostasis. It is surprising that
MDSCs in lal2/2 animal model share many characteristics used
by cancer cells.
Activation of G-protein superfamily
LAL deficiency leads to vast changes of the G-protein signaling
pathways (both large and small GTPases) in lal2/2 bone marrow
MDSCs (Table 1, 2, 3, 4, 5). Especially, multiple components of
small GTPases are up-regulated. Since G-protein signaling
pathways are well known for their diverse functions in cells (such
as glucose metabolism, ion channels, transcription, motility, and
secretion) [25,26], ups and downs of these genes exert their
profound pathological influences on MDSCs development and
homeostasis in lal2/2 mice. Among changed small GTPases, 1)
Ras GTPases activate the Raf/Mek/Erk pathway, which mediates
cell growth and cell-cycle entry by phosphorylation of transcription
factors, MNK (MAPK-interacting serine/threonine kinase) family
of kinases, and the PI3K/AKT pathway to control cell survival,
Figure 3. Cell cycle analysis of lal2/2 bone marrow MDSCs. A). Cell cycle analysis of CD11b
+ly6G
+ MDSCs from the bone marrow of lal+/+
mice and lal2/2 mice; B). The G1/G0 phase, S phase and G2/M phase of CD11b
+Ly6G
+ MDSCs from the bone marrow of lal+/+ mice and lal2/2 mice
were statistically analyzed. Results are means of 4 independent FACS experiments. n=4, **, p,0.01, *, p,0.5.
doi:10.1371/journal.pone.0030701.g003
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effectors were up-regulated (Table 3, 4, 5). For example, Erk
(Mapk3) was up to 7.3 folds, and p38 (Mapk13) was up to 5.1 folds.
We reported previously that the phosphorylation levels of both Erk
and p38 are substantially increased in lal2/2 bone marrow
MDSCs [4]; 2) Rho GTPases organize actin cytoskeleton, cell
adhesion and cell motility. They promote cell-cycle progression
throughG1byregulatingcyclinD1and cyclin-dependentinhibitors
p21 and p27 [19]; 3) Rab GTPases regulate receptor internaliza-
tion, vesicle formation and trafficking to various cellular sites,
including the nucleus, lysosome and plasma membrane. Through
regulation of endocytic trafficking, they integrate multiple signaling
pathways that are involved in cellular proliferation, apoptosis and
migration. Gene expression of multiple Rab GTPase-regulated
membrane vesicle traffic effectors that mediate vesicle intracellular
transport, including actin-dependent motors (myosins) or microtu-
bule-dependent motors (kinesins or dyneins) (Table S4), and
tethering factors (exocyst, trafficking protein particle complex or
TRAPPC, vacuole protein sorting or VPS) (Table S5) [27] were
significantly altered inlal2/2bone marrowMDSCs.Farnesylation
on G-proteins is a critical step for membrane binding and biological
function. Farnesyltransferaseexpression that farnesylates Ras on the
CAAX motif was increase 2 folds in lal2/2 bone marrow MDSCs
(Table 3, 4, 5).
Cell cycle and Histone cluster genes
The second group of disregulation in lal2/2 bone marrow
MDSCs belongs to cell cycle genes (Table 6). These cell cycle
Table 7. Gene expression changes of ubiquitination related
proteins in lal2/2 bone marrow MDSCs.
Genes Symbol Fold
ubiquitin specific peptidase 46 Usp46 5.4
OTU domain, ubiquitin aldehyde binding 1 Otub1 4.7
AN1, ubiquitin-like, homolog (Xenopus laevis) Anubl1 4.0
ubiquitin-conjugating enzyme E2G 2 Ube2g2 3.9
ubiquitin specific peptidase 39 Usp39 3.7
ubiquitin-like 4 Ubl4 3.5
ubiquitin-conjugating enzyme E2, J2 homolog (yeast) Ube2j2 3.0
ubiquitin-conjugating enzyme E2A, RAD6 homolog
(S. cerevis
Ube2a 2.9
ubiquitin-conjugating enzyme E2S Ube2s 2.9
ubiquitin fusion degradation 1 like Ufd1l 2.9
ubiquitin-like domain containing CTD phosphatase 1 Ublcp1 2.9
ubiquitin-conjugating enzyme E2N Ube2n 2.8
ubiquitin-fold modifier conjugating enzyme 1 Ufc1 2.7
ubiquitin-conjugating enzyme E2H Ube2h 2.6
ubiquitin-associated protein 1 Ubap1 2.6
ubiquitin-conjugating enzyme E2C Ube2c 2.5
ubiquitin specific peptidase 1 Usp1 2.4
WW domain containing E3 ubiquitin protein ligase 2 Wwp2 2.4
ubiquitin-fold modifier 1 Ufm1 2.4
similar to ubiquitin-conjugating enzyme E2N LOC635086 2.3
ubiquitin-like modifier activating enzyme 3 Uba3 2.3
ubiquitin-like modifier activating enzyme 2 Uba2 2.2
ubiquitin interaction motif containing 1 Uimc1 2.2
ubiquitin specific peptidase 5 (isopeptidase T) Usp5 2.2
ubiquitin-conjugating enzyme E2 variant 1 Ube2v1 2.2
ubiquitin-like 7 (bone marrow stromal cell-derived) Ubl7 2.2
ubiquitin-like 3 Ubl3 2.1
ubiquitin-like modifier activating enzyme 1 Uba1 2.1
ubiquitin-conjugating enzyme E2, J1 Ube2j1 2.1
ubiquitin specific peptidase 22 Usp22 2.1
HECT domain and ankyrin repeat containing,
E3 ubiquitin pr
Hace1 2.0
transmembrane and ubiquitin-like domain
containing 2
Tmub2 2.0
ubiquitin protein ligase E3 component n-recognin 2 Ubr2 2.0
ubiquitin-conjugating enzyme E2M (UBC12
homolog, yeast)
Ube2m 2.0
ubiquitin specific peptidase 31 Usp31 22.2
similar to ubiquitin-conjugating enzyme E2 va LOC635992 22.6
ubiquitin D Ubd 24.6
doi:10.1371/journal.pone.0030701.t007
Table 8. Gene expression changes of proteasome protein
subunits in lal2/2 bone marrow MDSCs.
Genes Symbol Fold
proteasome (prosome, macropain) subunit, beta type 3 Psmb3 8.5
proteasome (prosome, macropain) 26S subunit,
non-ATPase,
Psmd13 4.4
proteasome (prosome, macropain) 26S subunit,
non-ATPase,
Psmd10 3.6
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 8
Psmd8 3.3
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 4
Psmd4 3.1
proteasome (prosome, macropain) subunit, beta type 1 Psmb1 3.0
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 5
Psmd5 2.9
proteasome (prosome, macropain) subunit, beta type 6 Psmb6 2.7
proteasome (prosome, macropain) subunit, beta type 2 Psmb2 2.6
proteasome (prosome, macropain) subunit, alpha type 2 Psma2 2.5
proteasome (prosome, macropain) subunit, beta type 5 Psmb5 2.5
proteasome (prosome, macropain) 26S subunit, ATPase, 6 Psmc6 2.5
proteasome (prosome, macropain) subunit, beta type 7 Psmb7 2.4
proteasome (prosome, macropain) subunit, alpha type 1 Psma1 2.4
proteasome (prosome, macropain) 28 subunit, beta Psme2 2.4
proteasome (prosome, macropain) subunit, alpha type 7 Psma7 2.3
proteasome (prosome, macropain) 26S subunit, ATPase, 4 Psmc4 2.2
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 6
Psmd6 2.2
proteasome (prosome, macropain) subunit, beta type 4 Psmb4 2.1
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 7
Psmd7 2.1
proteasome (prosome, macropain) 26S subunit,
non-ATPase, 2
Psmd2 2.1
proteasome (prosome, macropain) 26S subunit, ATPase 2 Psmc2 2.1
proteasome (prosome, macropain) assembly chaperone 1 Psmg1 2.1
proteasome (prosome, macropain) subunit, alpha type 4 Psma4 2.1
doi:10.1371/journal.pone.0030701.t008
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checkpoints that sense possible defects during DNA synthesis
and chromosome segregation [21]. It has been demonstrated
that CDK1 (6.6 fold increase) alone can drive the cell cycle in
most mammalian cells [21]. Up-regulation of Cdk2, Cdk5,
Cdk9 suggests that lal2/2 bone marrow MDSCs acquire
specific needs for the activities of these Cdks during develop-
ment and homeostasis. Importantly, all Cdk regulatory cyclins
( A ,B ,D ,E - t y p e )t h a ta r er e q u i r e df o rp h a s ee n t e r i n go ft h ec e l l
cycle were up-regulated, suggesting constitutive mitogenic
signaling and defective responses to anti-mitogenic signals
under the pressure of Ras GTPases overactivation that
contribute to unscheduled proliferation during LAL deficiency.
Up-regulation of enzymes/protein factors that are involved in
ubiquitination and proteasome (Table 7 & 8) further suggests
the higher cell cycle activity in lal2/2 bone marrow MDSCs.
Ubiquitin and ubiquitin-like molecules direct proteins to
proteolysis within proteasome for recycling, which is required
in a wide variety of cellular processes, including cell cycle and
division, DNA transcription and repair, biogenesis of organelles,
modulation of cell surface receptors, ion channels and the
secretory pathway, response to stress and extracellular modu-
lators, ribosome biogenesis [21,28].
Another evidence of enhanced cell proliferation in lal2/2
bone marrow MDSCs is up-regulation of multiple members of
histone cluster genes (Table 9). Changes of these histone variants
and associate factors set up an epigenetic microenvironment that
preferentially favor certain gene expression and cellular events to
Table 9. Up-regulation of histone cluster genes in lal2/2
bone marrow MDSCs.
Genes Symbol Fold
histone cluster 1, H4d Hist1h4d 11.2
histone cluster 1, H4m Hist1h4m 9.4
histone cluster 1, H4f Hist1h4f 9.3
histone cluster 1, H2bc Hist1h2bc 8.1
histone cluster 1, H4b Hist1h4b 7.6
histone cluster 2, H4 Hist2h4 7.4
histone cluster 1, H2be Hist1h2be 6.7
histone cluster 1, H2bb Hist1h2bb 5.8
histone cluster 1, H2ab Hist1h2ab 5.2
histone cluster 1, H2an Hist1h2an 4.3
histone cluster 1, H2bm Hist1h2bm 4.2
histone cluster 1, H3g Hist1h3g 4.0
histone cluster 1, H3f Hist1h3f 3.9
histone cluster 1, H2ao Hist1h2ao 3.8
H1 histone family, member 0 H1f0 3.7
histone cluster 1, H2af Hist1h2af 3.7
histone cluster 4, H4 Hist4h4 3.6
H2A histone family, member X H2afx 3.6
histone cluster 1, H3a Hist1h3a 3.5
histone cluster 2, H3b Hist2h3b 3.5
histone cluster 2, H2aa1 Hist2h2aa1 3.5
H2A histone family, member Y2 H2afy2 3.1
histone cluster 2, H2bb Hist2h2bb 3.1
histone cluster 2, H3c1 Hist2h3c1 2.8
histone cluster 1, H2ak Hist1h2ak 2.7
H2A histone family, member Y H2afy 2.7
histone cluster 1, H4c Hist1h4c 2.6
histone cluster 1, H1b Hist1h1b 2.6
histone cluster 1, H2bh Hist1h2bh 2.3
histone cluster 1, H2bg Hist1h2bg 2.2
H2A histone family, member Z H2afz 2.1
H3 histone, family 3B H3f3b 2.0
histone cluster 1, H1a Hist1h1a 2.0
doi:10.1371/journal.pone.0030701.t009
Table 10. Gene expression changes of centromere protein
and chromosome structural genes in lal2/2 bone marrow
MDSCs.
Genes Symbol Fold
centromere protein H Cenph 6.1
centromere protein F Cenpf 4.2
centromere protein Q Cenpq 3.8
centromere protein K Cenpk 3.6
centromere protein J Cenpj 3.5
centromere protein L Cenpl 3.4
centromere protein E Cenpe 3.2
centromere protein P Cenpp 2.8
centromere protein A Cenpa 2.7
centromere protein O Cenpo 2.2
NUF2, NDC80 kinetochore complex component,
homolog (S. cerevisia
Nuf2 6.5
SPC25, NDC80 kinetochore complex component,
homolog (S. cerevisia
Spc25 6.5
SPC24, NDC80 kinetochore complex component,
homolog (S. cerevisia
Spc24 6.1
NDC80 homolog, kinetochore complex
component (S. cerevisia
Ndc80 3.6
kinetochore associated 1 Kntc1 2.1
Zwilch, kinetochore associated, homolog
(Drosophila)
Zwilch 2.1
Centrosomal protein 55 Cep55 4.9
nucleolar and spindle associated protein 1 Nusap1 3.8
structural maintenance of chromosomes 2 Smc2 3.6
spindle assembly 6 homolog (C. elegans) Sass6 3.5
chromatin modifying protein 4B Chmp4b 2.6
protection of telomeres 1A Pot1a 2.5
chromatin modifying protein 2A Chmp2a 2.4
inner centromere protein Incenp 2.3
chromatin modifying protein 5 Chmp5 2.3
regulator of chromosome condensation
(RCC1) and BTB (POZ)
Rcbtb2 2.2
chromatin accessibility complex 1 Chrac1 2.2
Centrosome and spindle pole associated protein 1 Cspp1 2.1
chromatin modifying protein 1B Chmp1b 2.1
chromodomain helicase DNA binding protein 7 Chd7 2.0
regulator of chromosome condensation (RCC1)
and BTB (POZ)
Rcbtb1 22.4
doi:10.1371/journal.pone.0030701.t010
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control gene expression, histone-variants exchange activities
contribute to formation of centromeric and telomeric chromatin
during cell cycles. A centromere is a region of DNA on
chromosome where two identical sister chromatids come closest
in contact. It is involved in cell division as the point of mitotic
spindle attachment. During mitotic division, kinetochore is
formed on top of the centromeres. The kinetochores are the
sites where the spindle fibers attach. Kinetochores and the spindle
apparatus are responsible for the movement of the two sister
chromatids to opposite poles of dividing cell nucleus during
anaphase. Up-regulation of centromeric and telomeric histones
along with other M phase chromosome structural proteins
demonstrated the increased activity of cell division in lal2/2
bone marrow MDSCs (Table 10). This was further supported by
the cell cycle analysis, in which lal2/2 bone marrow MDSCs in
G1/M phases were around 4 times more compared with wild
type MDSCs (Figure 3).
Metabolism and bioenergetics
Another similarity between lal2/2 bone marrow MDSCs and
cancer cells is reprogramming of energy metabolism. First, cells rely
on mitochondrial oxidative phosphorylation to provide energy
(ATP production) for cellular activities in normal conditions.
Cancer cells are characterized by increased glycolysis and reduced
mitochondrial respiratory function [24]. The electron flow through
the respiratory chain is substantially lower in malignant cells leading
to oxidative stress and increased ROS production. Similar to cancer
cells, multiple enzymes and proteins in glycolysis and citric acid
cycles were up-regulated in lal2/2 bone marrow MDSCs
(Table 11). Interestingly, the mitochondrial function in lal2/2
bone marrow MDSCs was impaired (Figure 4B) despite increased
expression of respiratory chain proteins (including NADH dehy-
drogenases, cytochrome proteins, ATPases and mitochondrial
ribosomal proteins) (Table 12, 13) and increased ATP production
(Figure 4 A) compared with those inwild type counterparts. Second,
pyruvate (the end product of glycolysis) is imported into
mitochondria and enters the citric acid cycle in normal cells.
Cancer cells use an altered metabolic pattern by taking up much
more glucose and mainly process it through aerobic glycolysis,
producing large quantities of secreted lactate by lactate dehydro-
genase (LDH) with a lower use of oxidative phosphorylation
Table 11. Up-regulation of metabolic enzyme genes in
glycolysis, citric acid cycle and glycogen syntheses in lal2/2
bone marrow MDSCs.
Genes of glycolysis Symbol Fold
hexokinase 2 Hk2 3.8
hexokinase 1 Hk1 3.2
hexokinase 3 Hk3 2.7
glucose phosphate isomerase 1 Gpi1 5.2
aldolase A, fructose-bisphosphate Aldoa 2.9
fructose bisphosphatase 1 Fbp1 11.0
triosephosphate isomerase 1 Tpi1 3.3
glyceraldehyde-3-phosphate dehydrogenase Gapdh 5.0
phosphoglycerate kinase 1 Pgk1 2.6
phosphoglycerate mutase 1 Pgam1 5.3
phosphoglucomutase 1 Pgm1 2.6
phosphoglucomutase 2 Pgm2 2.2
enolase 1, alpha non-neuron Eno1 6.0
pyruvate kinase, muscle Pkm2 2.2
solute carrier family 2 (facilitated glucose transporter),
or Glut3
Slc2a3 4.0
Genes of aerobic glycolysis
lactate dehydrogenase A Ldha 3.1
lactate dehydrogenase B Ldhb 2.7
Genes of citric acid cycle
pyruvate dehydrogenase kinase, isoenzyme 3 Pdk3 6.3
isocitrate dehydrogenase 1 (NADP+), soluble Idh1 4.5
Succinate dehydrogenase complex, subunit B, iron sulfur (Ip Sdhb 3.4
Succinate dehydrogenase complex, subunit B, iron sulfur (Ip Sdhb 3.4
malate dehydrogenase 2, NAD (mitochondrial) Mdh2 3.7
Genes of glycogen synthesis
liver glycogen phosphorylase Pygl 2.7
amylo-1,6-glucosidase, 4-alpha-glucanotransferase Agl 5.9
NM_028132//phosphoglucomutase 2 Pgm2 2.2
UDP-glucose pyrophosphorylase 2 Ugp2 2.4
glycogen synthase 1, muscle Gys1 6.1
doi:10.1371/journal.pone.0030701.t011
Figure 4. ATP production and mitochondrial potential analyses
of lal2/2 bone marrow MDSCs. A). ATP concentrations in Ly6G
+
MDSCs from the bone marrow of lal+/+ mice and lal2/2 mice. Results
are means of 4 independent experiments. n=3, **, p,0.01, *, p,0.5; B).
Mitochondrial membrane potential of CD11b
+Ly6G
+ MDSCs from the
bone marrow of lal+/+ mice and lal2/2 mice was analyzed by JC-1
staining. Positive staining of JC-1 red represents healthy mitochondria.
Transition from negative staining of JC-1 red to positive staining of JC-1
green represents impaired mitochondrial potential.
doi:10.1371/journal.pone.0030701.g004
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to cancers cells to allow them better surviving, producing
intermediates for cell growth and division. Similar to cancer cells,
lal2/2 bone marrow MDSCs showed increased gene expression of
both lactate dehydrogenase A and B (Table 11), which keep
pyruvate away from the mitochondria. This observation indicates
that LAL-controlled neutral lipid metabolism plays a critical role in
preventing metabolic switch from oxidative phosphorylation to
aerobic glycolysis in myeloid lineage cells.
In addition to generate energy for the cell (ATP) and produce
substrates to synthesize amino acids, nucleosides, and fatty acids,
normal cells use both glucose and glutamine as substrates to regulate
the redox potential to minimize the effects of reactive oxygen species
(ROS) that damage membranes, proteins and cause mutations in a
cell. Similar to cancer cells, the concentration of ROS was
significantly increased in lal2/2 bone marrow MDSCs (Figure 2B),
which was accompanied by up-regulation of nitric oxide/ROS
production genes (Figure 2A), glutathione peroxidase/glutathione
r e d u c t a s eg e n e s ,a n dg l u c o s e6 - p h o s p h a t ed e h y d r o g e n a s eg e n e( T a b l e
S2). High levels of ROS allow for the stimulation of cell proliferation,
induction of genetic instability, and evasion from senescence [23].
The mTOR pathway
Ingenuity Pathway Analysis revealed alteration in PI3K/
thymoma viral proto-oncogene (AKT)/mammalian target of
rapamycin (mTOR) signaling pathway [30,31,32] in lal2/2 bone
marrow MDSCs (Figure 1B). Activation of the mTOR pathway has
been confirmed by highly phosphorylated S6 and 4E-BP, two
authentic mTOR downstream effectors (Figure 1C). mTOR serves
as a signal integrator for nutrients, growth factors, energy and stress
[20]. Activation of this pathway suppresses apoptosis, promotes an
influx of glucose and amino acids into the cells, stimulates ATP
production [17], as well as contributes to cell growth, cell cycle
entry, cell survival, and cell motility during tumorigenesis [33].
Increasing evidence suggests that membrane trafficking causes
mTORC1to shuttle to lysosomes and regulate mTORC1signalling,
enabling it to respond to growth factors [20,34]. The lysosomal
surface hosts a molecular machinery for mTORC1 activation that
includes the Rag GTPases, the trimeric regulator complex, and
possibly GTPase activating proteins (GAPs) and guanine nucleotide
exchange factors (GEFs) for the Rag GTPases [20]. Since LAL is a
lysosome-associated enzyme, it is conceivable that lack of the LAL
activity may change lipid composition and dynamics on the
lysosomal membrane that influence endomembrane trafficking
and stimulate the mTOR1 activity, which in tune coordinates the
Table 12. Up and down-regulation of mitochondrial NADH
dehydrogenases in lal2/2 bone marrow MDSCs.
Genes Symbol Fold
NADH dehydrogenase (ubiquinone) Fe-S protein 5 Ndufs5 38.5
NAD(P)H dehydrogenase, quinone 2 Nqo2 6.3
NADH dehydrogenase Fe-S protein 5 pseudogene BC002163 4.9
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7 Ndufb7 4.4
NADH dehydrogenase (ubiquinone) flavoprotein 3 Ndufv3 4.3
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 Ndufa11 3.6
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 Ndufb8 3.6
NADH dehydrogenase (ubiquinone) Fe-S protein 4 Ndufs4 3.2
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 Ndufb6 3.2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 Ndufa11 3.2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 Ndufa7 3.1
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 Ndufa2 3.0
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 3 Ndufb3 2.9
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4 Ndufb4 2.9
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 Ndufa3 2.8
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 Ndufa8 2.7
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 Ndufa1 2.5
NADH dehydrogenase (ubiquinone) Fe-S protein 6 Ndufs6 2.4
NADH dehydrogenase (ubiquinone) flavoprotein 1 Ndufv1 2.4
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 Ndufb2 2.4
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 Ndufa13 2.3
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 Ndufb9 2.2
NADH dehydrogenase (ubiquinone) Fe-S protein 2//1 H3 Ndufs2 2.2
NAD(P)H dehydrogenase, quinone 1 Nqo1 2.2
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10 Ndufb10 2.2
NADH dehydrogenase (ubiquinone) flavoprotein 2 Ndufv2 2.1
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 Ndufa12 2.1
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 Ndufb11 2.0
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
asse
Ndufaf4 22.6
NADH dehydrogenase subunit 1 ND1 22.7
NADH dehydrogenase subunit 4L ND4L 24.0
doi:10.1371/journal.pone.0030701.t012
Table 13. Up-regulation of cytochrome and ATP synthesis
subunits in lal2/2 bone marrow MDSCs.
Genes of cytochrome subunits Symbol Fold
cytochrome b-245, alpha polypeptide Cyba 8.6
cytochrome b5 reductase 4 Cyb5r4 5.1
cytochrome c oxidase subunit VIb polypeptide 2 Cox6b2 3.4
cytochrome b5 reductase 4 Cyb5r4 3.4
ubiquinol-cytochrome c reductase (6.4 kD) subunit Uqcr 3.3
ubiquinol-cytochrome c reductase core protein 1 Uqcrc1 3.4
cytochrome P450, family 51 Cyp51 3.1
cytochrome P450, family 4, subfamily f, polypeptide 18 Cyp4f18 3.1
cytochrome b-245, beta polypeptide Cybb 2.9
cytochrome c-1 Cyc1 2.5
ubiquinol-cytochrome c reductase, complex III subunit VII Uqcrq 2.5
cytochrome c oxidase, subunit VIIa 2 Cox7a2 2.4
P450 (cytochrome) oxidoreductase Por 2.4
cytochrome c oxidase subunit IV isoform 1 Cox4i1 2.1
Genes of ATP synthase Symbol Fold
ATP synthase, H+ transporting, mitochondrial F1
complex, e
Atp5e 3.3
ATP synthase, H+ transporting, mitochondrial F0
complex, s
Atp5h 2.9
ATP synthase, H+ transporting, mitochondrial F1F0
complex,
Atp5k 2.5
ATP synthase, H+ transporting, mitochondrial F0
complex,
Atp5f1 2.1
ATP synthase, H+ transporting, mitochondrial F1
complex, d
Atp5d 2.1
doi:10.1371/journal.pone.0030701.t013
Gene Profile of lal2/2 Bone Marrow MDSCs
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e30701cellular metabolism and growth to increase abnormal proliferation
of lal2/2 bone marrow MDSCs.
I ti si m p o r t a n tt ok e e pi nm i n dt h a td e v e l o p m e n ta n de x p a n s i o no f
MDSCs are a complex process. In addition to changes of gene
expression, posttranscriptional modification of intracellular signaling
pathways also contributes to the lal2/2 MDSCsautonomousdefect.
For example, althoughup-regulationofStatsfamily memberswasnot
detected by Affymetrix GeneChip microarray analysis, phosphory-
lation of Stat3 at Y705 has been detected in expanded lal2/2
MDSCs [4]. Activation of Stat3 directly leads to MDSCs expansion
in vivo [35,36]. Phosphorylation of Erk and p38 in the Ras signaling
pathway has also been detected in expanded lal2/2 MDSCs.
In summary, studies outlined here demonstrate that the loss of
the LAL function leads to myeloproliferative neoplasm. Affymetrix
GeneChip microarray analysis provides a detailed map of intrinsic
defects existing in lal2/2 bone marrow MDSCs. The interrela-
tionships between these biological processes during lal2/2
MDSCs development and homeostasis remain to be elucidated
in the future. The study provides new avenues and interventions
clinically to eliminate MDSCs expansion in disease setting.
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